<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067909</url>
  </required_header>
  <id_info>
    <org_study_id>HNM_V1</org_study_id>
    <nct_id>NCT03067909</nct_id>
  </id_info>
  <brief_title>Antithrombotic Therapy in Patients Undergoing CIED Surgery - HEMATOMA NO MORE Registry</brief_title>
  <official_title>THE Management of AntiThrOMbotic therApy in Patients Undergoing Electrophysiological Device Surgery: Italian NatiOnal Multicenter Observational REgistry (HEMATOMA NO MORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Senese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Senese</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hundreds of thousands patients undergo implantation or replacement of cardiac implantable
      electronic devices (CIEDs) annually in Europe, and up to 50% of these subjects receive
      antiplatelet agents or oral anticoagulants. Antithrombotic therapy increases the risk of
      developing pocket hematoma which in turn is associated with an increased risk of potentially
      fatal device-related infections when clinically significant. Aim of the registry is to
      retrospectively (pilot local registry in Tuscany) and prospectively (multicenter national
      registry in Italy) investigate the different strategies for the management of antithrombotic
      therapy and the related complication rates (1-month and 12-months) in patients undergoing
      CIED surgery in a real-world setting. The registry will also provide data on the economic
      impact of different management strategies and complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Clinically significant pocket hematoma</measure>
    <time_frame>One month</time_frame>
    <description>Post-procedural hematoma resulting in prolonged hospitalization and/or requiring interruption of antithrombotic therapy and/or requiring further surgery and/or requiring transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-clinically significant pocket hematoma</measure>
    <time_frame>One month</time_frame>
    <description>Post-procedural hematoma not meeting diagnostic criteria for clinically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic complications other than pocket hematoma</measure>
    <time_frame>One month</time_frame>
    <description>Hemothorax, cardiac tamponade, pericardial effusion, intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>Twelve months</time_frame>
    <description>Transient ischemic attack, ischemic stroke, deep venous thrombosis, pulmonary embolism, systemic embolic event, acute myocardial infarction, prosthetic cardiac valve thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>Twelve months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIED-related infection</measure>
    <time_frame>Twelve months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1450</enrollment>
  <condition>Device Related Infection</condition>
  <condition>Antithrombotic Drugs</condition>
  <condition>Cardiac Arrhythmia</condition>
  <condition>Surgery--Complications</condition>
  <condition>Hematoma</condition>
  <arm_group>
    <arm_group_label>Patients undergoing CIED surgery</arm_group_label>
    <description>Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CIED surgery</intervention_name>
    <arm_group_label>Patients undergoing CIED surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients taking antithrombotic therapy undergoing CIED surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with standard indications to CIED surgery being treated with antiplatelet
             agents and/or anticoagulants (any commercially available device or approved and
             marketed drug can be included).

          -  Patients able to provide written informed consent

          -  Patients willing to attend the planned follow-up visits

        Exclusion Criteria:

          -  Patient with life expectancy less than 12 months as per investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerio Zacà, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Senese</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOU Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Zacà V, Breschi M, Mandorli A, Panchetti L, Ricciardi G, Viani S, Notarstefano P. Rationale, study design, and pilot phase of tHE Management of AntiThrOMbotic therApy (HEMATOMA) in patients undergoing electrophysiological device surgery: Italian National Multicenter Observational REgistry. J Cardiovasc Med (Hagerstown). 2017 Nov;18(11):897-899. doi: 10.2459/JCM.0000000000000534.</citation>
    <PMID>28594654</PMID>
  </reference>
  <reference>
    <citation>V Zaca', A Angeletti, C Baiocchi, M Bertini, M Biffi, P Busacca, M Iori, M Mezzetti, M Nesti, P Notarstefano; P3213 Real-world periprocedural management of antithrombotic therapy in patients undergoing electrophysiological device surgery: preliminary results of the HEMATOMA NO MORE, European Heart Journal, Volume 39, Issue suppl_1, 1 August 2018, ehy563.P3213, https://doi.org/10.1093/eurheartj/ehy563.P3213</citation>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 25, 2017</study_first_submitted>
  <study_first_submitted_qc>February 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Senese</investigator_affiliation>
    <investigator_full_name>Valerio Zacà</investigator_full_name>
    <investigator_title>Principal Investigator, Cardiology Consultant, Arrhythmology Unit, Cardiothoracic and Vascular Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prosthesis-Related Infections</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be made available on demand to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

